{
    "root": "470788b4-fbba-4d33-9fd2-ed3cb67064b0",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Clopidogrel bisulfate",
    "value": "20250307",
    "ingredients": [
        {
            "name": "Clopidogrel bisulfate",
            "code": "08I79HTP27"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "HYDROGENATED CASTOR OIL",
            "code": "ZF94AP8MEY"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "Clopidogrel is a P2Y 12 platelet inhibitor indicated for: • Acute coronary syndrome o For patients with non–ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) o For patients with ST-elevation myocardial infarction (STEMI), clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel has been shown to reduce the rate of MI and stroke. ( 1.2 )",
    "contraindications": "• Acute coronary syndrome ( 2.1 ) o Initiate clopidogrel with a single 300-mg oral loading dose and then continue at 75 mg once daily. o Initiate clopidogrel without a loading dose will delay establishment of an antiplatelet effect by several days. • Recent MI, recent stroke, or established peripheral arterial disease: 75 mg once daily orally without a loading dose ( 2.2 )",
    "warningsAndPrecautions": "Clopidogrel tablets, USP 75 mg are available as pink colored, round shaped, biconvex, film coated tablets de-bossed on one side with SG and 124 on other side. Tablets are provided as follows:  \n                  \n                     \n                     \n                     \n                        \n                           \n                              NDC 68788-7700-03\n                           \n                           \n                              Bottles of 30\n                           \n                        \n                        \n                           \n                              NDC 68788-7700-06\n                           \n                           \n                              Bottles of 60\n                           \n                        \n                        \n                           \n                              NDC 68788-7700-09\n                           \n                           \n                              Bottles of 90\n                           \n                        \n                     \n                  \n                  Store at 25° C (77° F); excursions permitted to 15° to 30° C (59° to 86° F) [see USP Controlled Room Temperature].",
    "adverseReactions": "• Active pathological bleeding, such as peptic ulcer or intracranial hemorrhage ( 4.1 ) • Hypersensitivity to clopidogrel or any component of the product ( 4.2 )"
}